tbuckley/cabot-search huggingface dataset:
Iron Loading Anemia: Treatment with Pyridoxine and Repeated Phlebotomies.
Authors: Lewis R. Weintraub, Marcel E. Conrad, William H. Crosby
Journal: Annals of Internal Medicine (1964)

s1 April 1964Iron Loading Anemia: Treatment with Pyridoxine and Repeated Phlebotomies.Lewis R. Weintraub, Marcel E. Conrad, William H. CrosbyLewis R. WeintraubSearch for more papers by this author, Marcel E. ConradSearch for more papers by this author, William H. CrosbySearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-60-4-728_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIron-loading anemias are characterized by: (1) hypochromic microcytic red cells, (2) elevated serum iron with saturated TIBC, (3) siderosis of body tissues, and (4) sideroblasts in the bone marrow and circulating siderocytes. Two cases are presented which demonstrated a partial hematologic response after pyridoxine therapy. Iron59studies revealed increased intestinal absorption and poor red cell utilization of iron before and after therapy. These findings explained the excessive siderosis of the liver and bone marrow which was seen in biopsy material from both cases. Energetic phlebotomy therapy was then instituted. Approximately 7 g of iron were removed from one patient during... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByPyridoxine-Responsive Anemia—Prototype and Variations on the Theme 1 April 1964Volume 60, Issue 4Page: 728-728KeywordsAnemiaBiopsyBone marrowCellsLiverPhlebotomyPyridoxineTotal iron binding capacity Issue Published: 1 April 1964 PDF DownloadLoading ...
Effects of Iron Loading on Pathogenicity in Hepatitis C Virus-Infected Chimpanzees
Authors: Suzanne E. Bassett, Adrian M. Di Bisceglie, Bruce R. Bacon, Mark R. Sharp, Sugantha Govindarajan, Gene B. Hubbard, Kathleen M. Brasky, Robert E. Lanford
Journal: Hepatology (1999)

Elevated iron levels have been associated with raised serum alanine transaminase (ALT) levels in hepatitis C virus (HCV)–infected humans. However, it is not clear if HCV infection causes increased iron accumulation by the liver or if the severity of HCV infection is actually worsened by higher iron levels in the host. To better understand the relationship between iron and persistent HCV infections, we examined the effect of excess dietary iron on disease severity in HCV–infected chimpanzees. Iron was supplemented in the diets of four HCV–infected and two uninfected chimpanzees for 29 weeks to achieve iron loading. Iron loading was confirmed by increases in serum iron levels, percentages of transferrin saturation, ferritin levels, elevations in hepatic iron concentration (HIC), and by histological examination. The majority of HCV–infected chimpanzees had higher iron levels before iron feeding than the uninfected animals. Although various degrees of iron loading occurred in all chimpanzees, HCV–infected animals exhibited increased loading in comparison with uninfected animals. The effects of iron loading on HCV disease expression was determined by comparing disease parameters during an extended baseline period before iron loading with the period during iron loading and immediately following iron loading. Iron loading did not influence the viral load, but did exacerbate liver injury in HCV–infected chimpanzees, as evidenced by elevated ALT and histological changes. Because all chimpanzees on high iron diets experienced iron loading, but pathological effects were only observed in HCV–infected chimpanzees, HCV infection appears to increase the susceptibility of the liver to injury following iron loading. These results confirm and extend previous observations made in human populations and serve to further validate the chimpanzee model of chronic hepatitis C.
Hypertension Due to Primary Renal Ischemia
Authors: D. W. Crocker, R. A. Newton, Edward M. Mahoney, J. Hartwell Harrison
Journal: New England Journal of Medicine (1962)

THE literature now contains incontrovertible evidence that some forms of severe hypertension in man can be cured by revascularization or by nephrectomy.1 , 4 The prime example is hypertension associated with relative renal ischemia, the most clearcut mechanism being partial obstruction to renal-artery flow, similar in many respects to the "Goldblatt kidney" in dog,.5 , 6 From time to time, interest has centered on the juxtaglomerular apparatus in these kidneys. The juxtaglomerular apparatus consists of the macula densa and the juxtaglomerular body. The latter is made up of epithelioid cells grouped about the afferent arteriole. Goormaghtigh7 first postulated an endocrine function for the juxtaglomerular . . .
Additive Effects of Phosphodiesterase-4 Inhibition on Effects of rSP-C Surfactant
Authors: DIETRICH HÄFNER, PAUL-GEORG GERMANN
Journal: American Journal of Respiratory and Critical Care Medicine (2000)

We have tested the effects of combined treatment with a recombinant surfactant protein C based surfactant (rSP-C surfactant) containing a phosphodiesterase-4 (PDE-4) inhibitor, roflumilast, in a lung lavage model of acute lung injury. The following groups were tested: (1) controls receiving sham exposure; (2) PDE-4 inhibitor (6.0 mg/kg body weight, intratracheally) alone; (3, 4) rSP-C surfactant (25 and 100 mg phospholipids [PL] per kg body weight) alone; and (5, 6 ) treatment with rSP-C surfactant (25 and 100 mg PL per kg body weight) combined with the PDE-4 inhibitor at a dose of 6.0 mg/kg body weight. The different groups were compared with respect to improving oxygenation and histopathologic changes, e.g., hyaline membrane (HM) formation. Both doses of rSP-C surfactant improved oxygenation while even this high dose of the PDE-4 inhibitor alone did not influence oxygenation compared with untreated control animals. Addition of the PDE-4 inhibitor led to improved oxygenation based on both doses of rSP-C surfactant. The PDE-4 inhibitor alone prevented further HM formation and infiltration of neutrophil leukocytes. The rSP-C surfactant was able to prevent further HM formation. Based on both doses of rSP-C surfactant, addition of the PDE-4 inhibitor showed additional effects on oxygenation and inhibition of HM formation. The effects of combined treatment were superior to each treatment alone, leading to the conclusion that a rSP-C surfactant containing a PDE-4 inhibitor may act synergistically in this animal model of acute lung injury. We conclude that combined treatment with rSP-C surfactant and a PDE-4 inhibitor may be an effective treatment for patients with acute lung injury.
Scarring of the concha as a sign of lupus erythematosus
Authors: A. Rebora
Journal: British Journal of Dermatology (1982)

Journal Article Scarring of the concha as a sign of lupus erythematosus Get access A. Rebora A. Rebora Clinica Dermatologica R, University of Genoa, Italy Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 106, Issue 1, 1 January 1982, Page 122, https://doi.org/10.1111/j.1365-2133.1982.tb00916.x Published: 01 January 1982
Unusual geodes ('bone cysts') in rheumatoid arthritis.
Authors: M I Jayson, A S Dixon, P Yeoman
Journal: Annals of the Rheumatic Diseases (1972)

The geologists' term 'geode' is used in continental Europe to describe the radiological appearance of cavities in the bone ends in patients with various forms of arthritis (Jayson, Rubenstein, and Dixon, 1970).We describe here a patient with rheumatoid arthritis and unusually large geodes, the contents of which were calcified-an appearance which, we believe, has not previously been described.Clinical findings A 60-year old male clerk had suffered from classical nodular seropositive rheumatoid arthritis for 20 years.He had been treated with tetracosactrin for 2 years and had been working until 18 months before admission to hospital.He had been unable to walk for the previous 5 months.The knee joints were the most severely affected.
Gentamicin and Ticarcillin Levels
Authors: Larry K. Pickering, Thomas G. Cleary, Charles D. Ericsson
Journal: JAMA (1980)

<h3>To the Editor.—</h3> The article by Murillo et al (241:2401, 1979) entitled "Gentamicin and Ticarcillin Serum Levels" reported that mean concentrations of gentamicin sulfate and ticarcillin disodium in adult patients with neutropenia who received gentamicin plus ticarcillin were substantially lower than concentrations of gentamicin in patients receiving gentamicin plus cephalothin sodium or ticarcillin in patients receiving ticarcillin and cephalothin. Postulated mechanisms for these observations were differences in renal excretion between the groups and chemical interaction between ticarcillin and gentamicin with subsequent inactivation. The three groups described by Murillo et al differed with regard to age. The patients with low concentrations of ticarcillin and gentamicin in serum were younger (mean, 37.6 years) than patients in the groups receiving ticarcillin plus cephalothin (mean, 50.9 years) or cephalothin plus gentamicin (mean, 50.3 years). The glomerular filtration rate (GFR) as measured by inulin clearance is age related.<sup>1</sup>Representative values are listed in the
Dieulafoy’s Lesion of the Esophagus Correctly Diagnosed and Successfully Treated by the Endoscopic Injection of N-Butyl-2-Cyanoacrylate
Authors: T. Yoshida, K. Adachi, Y. Tanioka, T. Sasaki, S. Ono, H. Hanada, T. Esaki, T. Yagawa, S. Takeo, Y. Saiki, T. Harada, K. Okita
Journal: Endoscopy (2004)

Dieulafoy's lesion is an arterial malformation in the subumucosal layer of the gastrointestinal tract that can cause massive bleeding. The esophagus is not a common location for this lesion. We present here a first report of Dieulafoy's lesion of the esophagus correctly diagnosed and successfully treated by the endoscopic injection of N-butyl-2-cyanoacrylate.
Remarks ON BONE GRAFTING AS AN AID IN TREATMENT OF TUBERCULOUS SPINAL CARIES
Authors: H. M. W. Gray
Journal: BMJ (1922)

73~~~~by my friond Dr. Doualas Gutthrie, 'I was struck by a peculiar movement in the neck.Thle patient had been for a short time under chloroform, and I observed wlhat seemed to bq the pulsation of a vein, wlichl extended from the left clavicle near its inner erd half-way up the neck.The movement was perfectly regular at 60 beats a minute.When I fe.lt the pulse and watclhed the veins in the neck I discovered that tllere was no relation between this curious beatiug and the arterial and venous pulse, the latter beating about 80 a minute, with frequent intermissions due to extra-systoles.Looking more closely at thie movement and feeling -it with the finger, it
Effective health care: Cochrane database accessible in Scotland
Authors: C Wilkinson, I Johnstone, J Hayward, J A D Spencer, H Lewison
Journal: BMJ (1994)

EDITOR, - It is a pity that Sara Paterson - Brown and colleagues confined their review of the dissemination of the Cochrane database of randomised controlled trials to England,1 for in Scotland the situation is different. All 23 consultant obstetric maternity units in Scotland had access to the Cochrane database by the end of 1993. The database is on a specially installed personal computer in the work station of each labour ward. Thus both doctors and midwives have access to it not only for personal study but to assist in clinical decision making at the point where decisions are being made. A printer has also been provided to allow output to be taken home …
A Crossover Study Comparing the Kinetics of Tc-99m-labeled Diethyl- and Diisopropyl-IDA
Authors: MANUEL HERNANDEZ, LEONARD ROSENTHALL
Journal: Clinical Nuclear Medicine (1980)

Tc-99m-diisopropyl-IDA (DISIDA) and Tc-99m-diethyl- IDA (DE-IDA) were compared in each of 44 patients who had serum bilirubin levels ranging from normal to 50 mg/dl. Quantitative and qualitative analysis showed a significantly higher liver uptake relative to background for DISIDA. No significant differences between DISIDA and DE-IDA were found in the blood retention and rate of liver washout. Clinically, the diagnostic information received from both radiopharmaceuticals was essentially the same.
Iron oxide core oil-in-water emulsions as a multifunctional nanoparticle platform for tumor targeting and imaging
Authors: Peter A. Jarzyna, Torjus Skajaa, Anita Gianella, David P. Cormode, Daniel D. Samber, Stephen D. Dickson, Wei Chen, Arjan W. Griffioen, Zahi A. Fayad, Willem J.M. Mulder
Journal: Biomaterials (2009)
ABC of sleep disorders. Withdrawal from hypnotic drugs.
Authors: P Tyrer
Journal: BMJ (1993)

As well as the traditional sedative/hypnotic group of drugs that relieve anxiety by day and promote sleep at night there are several other groups of drugs that are used to treat insomnia-particularly antidepressant, antipsychotic, and antihistamine drugs.As they differ substantially in their pharmacological and clinical effects on withdrawal I will consider them separately.
High Residual Platelet Reactivity and Thrombotic Events
Authors: T. Cuisset, P.-E. Morange, M.-C. Alessi
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Contribution of organic particulates to respiratory cancer.
Authors: G Matanoski, L Fishbein, C Redmond, H Rosenkranz, L Wallace
Journal: Environmental Health Perspectives (1986)

This paper presents some of the issues that remain to be resolved in order to assess the risk of cancer related to exposure to organic particulates. Most reviews of the effects of organic particulates from the outdoor environment on the risk of lung cancer show that this source seems to play a minor role. However, as fuel use and chemical composition of air pollutants change, the contribution of outdoor pollution as a cause of cancer may also change. Indoor air pollution is a more important source of exposure to organic particulates than is outdoor exposure. Although there is clear evidence that in occupational settings organic particulates cause human cancer, there has been almost no study of exposure to these types of particulates within indoor settings. Previous research has focused on cigarette smoke as the major indoor pollutant, but more specific characterization of contaminants in both the workplace and the home is required. The health effects of the higher levels of some of these contaminants in the workplace should be evaluated and the results extrapolated to populations exposed to lower levels in the home. Extensive research is needed to characterize organic particulate mixtures appropriately and test them for carcinogenicity. Studies on the health risks of nitropolynuclear aromatic hydrocarbons and polychlorinated dibenzodioxins and dibenzofurans are reviewed, but their contribution to the overall burden of respiratory cancer in humans cannot be estimated at this time. Characterization of mixtures, assessment of exposures, and linkage of exposures to health effects are the objectives of the recommendations proposed for further research.
High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2
Authors: Giovanna Maria Pierantoni, Cinzia Rinaldo, Marcella Mottolese, Anna Di Benedetto, Francesco Esposito, Silvia Soddu, Alfredo Fusco
Journal: Journal of Clinical Investigation (2007)

High-mobility group A1 (HMGA1) overexpression and gene rearrangement are frequent events in human cancer, but the molecular basis of HMGA1 oncogenic activity remains unclear. Here we describe a mechanism through which HMGA1 inhibits p53-mediated apoptosis by counteracting the p53 proapoptotic activator homeodomain-interacting protein kinase 2 (HIPK2). We found that HMGA1 overexpression promoted HIPK2 relocalization in the cytoplasm and inhibition of p53 apoptotic function, while HIPK2 overexpression reestablished HIPK2 nuclear localization and sensitivity to apoptosis. HIPK2 depletion by RNA interference suppressed the antiapoptotic effect of HMGA1, which indicates that HIPK2 is the target required for HMGA1 to repress the apoptotic activity of p53. Consistent with this process, a strong correlation among HMGA1 overexpression, HIPK2 cytoplasmic localization, and low spontaneous apoptosis index (comparable to that observed in mutant p53-carrying tumors) was observed in WT p53-expressing human breast carcinomas. Hence, cytoplasmic relocalization of HIPK2 induced by HMGA1 overexpression is a mechanism of inactivation of p53 apoptotic function that we believe to be novel.
Increased prevalence of pre-school wheeze is not explained by time trends in body mass index
Authors: Myrofora Goutaki, Anina M. Pescatore, Parvinder Singh, Caroline S. Beardsmore, Claudia E. Kuehni
Journal: European Respiratory Journal (2014)

To the Editor: 

Overweight and obesity have been associated with asthma, particularly in adults [1–4]. In children, findings are less consistent [2, 5–7]. Different mechanisms have been proposed to explain this association, including lung mechanics, systemic inflammation and associated comorbidities [1, 2, 8]. In a previous study, we showed that the prevalence of pre-school wheeze doubled in two cohorts in Leicestershire, UK, born 8 years apart [9]. This increase could not be attributed to differences in environmental exposures, socioeconomic status or vaccination status [9, 10]. Because body mass index (BMI) is increasing across the globe [2], we hypothesised that BMI played a role. We therefore sought to determine whether higher BMI in the second cohort could explain the increase in prevalence of pre-school wheezing and asthma.

Our data come from the Leicester Respiratory Cohorts, two population-based random samples of children living in Leicestershire [11]. Cohort 1 included children born in 1985–1989; cohort 2 included children born in 1993–1997. At the time the first respiratory questionnaire was administered (1990 and 1998), children were 1–4 years old. An identical study protocol was followed for both cohorts [11]. Parents completed a postal questionnaire that asked for detailed information on respiratory symptoms and environmental exposures. Routine data, including demographic and ethnic information, and data on growth and immunisations, were available from the Leicestershire Health Authority Database. Height and weight had been measured and recorded independently by health visitors. We used the measurements made closest to the date of the questionnaire for analyses. The Leicestershire Health Authority Research Ethics Committee (Leicester, UK) approved the study.

We included white pre-school children aged 1–4.99 years, with completed questionnaires and at least one valid …
THE RELATIONSHIP BETWEEN THE TIME OF ONSET OF LEFT VENTRICULAR WALL MOTION ABNORMALITY DURING EXERCISE AND THE PRESENCE AND SEVERITY OF CORONARY ARTERY DISEASE
Authors: Asher Kimchi, Alan Rozanski, Caryl Fletcher, Jamshid Maddahi, Franklin Murphy, Steven Reisman, H. J.C. Swan, Daniel Berman
Journal: Clinical Nuclear Medicine (1982)

Kimchi, Asher; Rozanski, Alan; Fletcher, Caryl; Maddahi, Jamshid; Murphy, Franklin; Reisman, Steven; Swan, H. J.C.; Berman, Daniel Author Information
Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients With Diabetes and Coronary Artery Disease
Authors: Rhonda M. Cooper-DeHoff, Yan Gong, Eileen M. Handberg, Anthony A. Bavry, Scott J. Denardo, George L. Bakris, Carl J. Pepine
Journal: JAMA (2010)

<h3>Context</h3>Hypertension guidelines advocate treating systolic blood pressure (BP) to less than 130 mm Hg for patients with diabetes mellitus; however, data are lacking for the growing population who also have coronary artery disease (CAD).<h3>Objective</h3>To determine the association of systolic BP control achieved and adverse cardiovascular outcomes in a cohort of patients with diabetes and CAD.<h3>Design, Setting, and Patients</h3>Observational subgroup analysis of 6400 of the 22 576 participants in the International Verapamil SR-Trandolapril Study (INVEST). For this analysis, participants were at least 50 years old and had diabetes and CAD. Participants were recruited between September 1997 and December 2000 from 862 sites in 14 countries and were followed up through March 2003 with an extended follow-up through August 2008 through the National Death Index for US participants.<h3>Intervention</h3>Patients received first-line treatment of either a calcium antagonist or β-blocker followed by angiotensin-converting enzyme inhibitor, a diuretic, or both to achieve systolic BP of less than 130 and diastolic BP of less than 85 mm Hg. Patients were categorized as having tight control if they could maintain their systolic BP at less than 130 mm Hg; usual control if it ranged from 130 mm Hg to less than 140 mm Hg; and uncontrolled if it was 140 mm Hg or higher.<h3>Main Outcome Measures</h3>Adverse cardiovascular outcomes, including the primary outcomes which was the first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke.<h3>Results</h3>During 16 893 patient-years of follow-up, 286 patients (12.7%) who maintained tight control, 249 (12.6%) who had usual control, and 431 (19.8%) who had uncontrolled systolic BP experienced a primary outcome event. Patients in the usual-control group had a cardiovascular event rate of 12.6% vs a 19.8% event rate for those in the uncontrolled group (adjusted hazard ratio [HR], 1.46; 95% confidence interval [CI], 1.25-1.71; P &lt; .001). However, little difference existed between those with usual control and those with tight control. Their respective event rates were 12.6% vs 12.7% (adjusted HR, 1.11; 95% CI, 0.93-1.32; P = .24). The all-cause mortality rate was 11.0% in the tight-control group vs 10.2% in the usual-control group (adjusted HR, 1.20; 95% CI, 0.99-1.45; P = .06); however, when extended follow-up was included, risk of all-cause mortality was 22.8% in the tight control vs 21.8% in the usual control group (adjusted HR, 1.15; 95% CI, 1.01-1.32; P = .04).<h3>Conclusion</h3>Tight control of systolic BP among patients with diabetes and CAD was not associated with improved cardiovascular outcomes compared with usual control.<h3>Trial Registration</h3>clinicaltrials.gov Identifier: NCT00133692